{"id":29375,"date":"2020-07-17T06:23:54","date_gmt":"2020-07-17T06:23:54","guid":{"rendered":"https:\/\/www.healthbenefitstimes.com\/glossary\/?p=29375"},"modified":"2020-07-17T06:23:54","modified_gmt":"2020-07-17T06:23:54","slug":"serotonin-dopamine-antagonists-sdas","status":"publish","type":"post","link":"https:\/\/www.healthbenefitstimes.com\/glossary\/serotonin-dopamine-antagonists-sdas\/","title":{"rendered":"Serotonin-dopamine antagonists (SDAs)"},"content":{"rendered":"<p>A class of medications known as the atypical antipsychotics. both conventional antipsychotics and atypical antipsychotics are antagonists of dopamine receptors; however, the newer agents are also potent antagonists of serotonin receptors (5-HT2A). As a result of this distinctive receptor profile, SDAs may be more effective than conventional antipsychotics in reducing negative symptoms of schizophrenia. they also may produce fewer extrapyramidal symptoms (EPS) and decrease the risk for developing tardive dyskinesia with long-term use; however, SDAs and conventional antipsychotics are equally effective in treating the positive symptoms of schizophrenia.<\/p>\n<hr \/>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A class of medications known as the atypical antipsychotics. both conventional antipsychotics and atypical antipsychotics are antagonists of dopamine receptors; however, the newer agents are also potent antagonists of serotonin receptors (5-HT2A). As a result of this distinctive receptor profile, SDAs may be more effective than conventional antipsychotics in reducing negative symptoms of schizophrenia. they [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[],"class_list":["post-29375","post","type-post","status-publish","format-standard","hentry","category-s"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Serotonin-dopamine antagonists (SDAs) - Definition of Serotonin-dopamine antagonists (SDAs)<\/title>\n<meta name=\"description\" content=\"A class of medications known as the atypical antipsychotics. both conventional antipsychotics and atypical antipsychotics are antagonists of dopamine receptors; however, the newer agents are also potent antagonists of serotonin receptors (5-HT2A). As a result of this distinctive receptor profile, SDAs may be more effective than conventional antipsychotics in reducing negative symptoms of schizophrenia. they also may produce fewer extrapyramidal symptoms (EPS) and decrease the risk for developing tardive dyskinesia with long-term use; however, SDAs and conventional antipsychotics are equally effective in treating the positive symptoms of schizophrenia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.healthbenefitstimes.com\/glossary\/serotonin-dopamine-antagonists-sdas\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Serotonin-dopamine antagonists (SDAs) - Definition of Serotonin-dopamine antagonists (SDAs)\" \/>\n<meta property=\"og:description\" content=\"A class of medications known as the atypical antipsychotics. both conventional antipsychotics and atypical antipsychotics are antagonists of dopamine receptors; however, the newer agents are also potent antagonists of serotonin receptors (5-HT2A). As a result of this distinctive receptor profile, SDAs may be more effective than conventional antipsychotics in reducing negative symptoms of schizophrenia. they also may produce fewer extrapyramidal symptoms (EPS) and decrease the risk for developing tardive dyskinesia with long-term use; however, SDAs and conventional antipsychotics are equally effective in treating the positive symptoms of schizophrenia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.healthbenefitstimes.com\/glossary\/serotonin-dopamine-antagonists-sdas\/\" \/>\n<meta property=\"og:site_name\" content=\"Glossary\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-17T06:23:54+00:00\" \/>\n<meta name=\"author\" content=\"Glossary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Glossary\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/serotonin-dopamine-antagonists-sdas\/\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/serotonin-dopamine-antagonists-sdas\/\",\"name\":\"Serotonin-dopamine antagonists (SDAs) - Definition of Serotonin-dopamine antagonists (SDAs)\",\"isPartOf\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\"},\"datePublished\":\"2020-07-17T06:23:54+00:00\",\"dateModified\":\"2020-07-17T06:23:54+00:00\",\"author\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\"},\"description\":\"A class of medications known as the atypical antipsychotics. both conventional antipsychotics and atypical antipsychotics are antagonists of dopamine receptors; however, the newer agents are also potent antagonists of serotonin receptors (5-HT2A). As a result of this distinctive receptor profile, SDAs may be more effective than conventional antipsychotics in reducing negative symptoms of schizophrenia. they also may produce fewer extrapyramidal symptoms (EPS) and decrease the risk for developing tardive dyskinesia with long-term use; however, SDAs and conventional antipsychotics are equally effective in treating the positive symptoms of schizophrenia.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/serotonin-dopamine-antagonists-sdas\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.healthbenefitstimes.com\/glossary\/serotonin-dopamine-antagonists-sdas\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/serotonin-dopamine-antagonists-sdas\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Serotonin-dopamine antagonists (SDAs)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\",\"name\":\"Glossary\",\"description\":\"Difinitions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\",\"name\":\"Glossary\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Serotonin-dopamine antagonists (SDAs) - Definition of Serotonin-dopamine antagonists (SDAs)","description":"A class of medications known as the atypical antipsychotics. both conventional antipsychotics and atypical antipsychotics are antagonists of dopamine receptors; however, the newer agents are also potent antagonists of serotonin receptors (5-HT2A). As a result of this distinctive receptor profile, SDAs may be more effective than conventional antipsychotics in reducing negative symptoms of schizophrenia. they also may produce fewer extrapyramidal symptoms (EPS) and decrease the risk for developing tardive dyskinesia with long-term use; however, SDAs and conventional antipsychotics are equally effective in treating the positive symptoms of schizophrenia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.healthbenefitstimes.com\/glossary\/serotonin-dopamine-antagonists-sdas\/","og_locale":"en_US","og_type":"article","og_title":"Serotonin-dopamine antagonists (SDAs) - Definition of Serotonin-dopamine antagonists (SDAs)","og_description":"A class of medications known as the atypical antipsychotics. both conventional antipsychotics and atypical antipsychotics are antagonists of dopamine receptors; however, the newer agents are also potent antagonists of serotonin receptors (5-HT2A). As a result of this distinctive receptor profile, SDAs may be more effective than conventional antipsychotics in reducing negative symptoms of schizophrenia. they also may produce fewer extrapyramidal symptoms (EPS) and decrease the risk for developing tardive dyskinesia with long-term use; however, SDAs and conventional antipsychotics are equally effective in treating the positive symptoms of schizophrenia.","og_url":"https:\/\/www.healthbenefitstimes.com\/glossary\/serotonin-dopamine-antagonists-sdas\/","og_site_name":"Glossary","article_published_time":"2020-07-17T06:23:54+00:00","author":"Glossary","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Glossary"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/serotonin-dopamine-antagonists-sdas\/","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/serotonin-dopamine-antagonists-sdas\/","name":"Serotonin-dopamine antagonists (SDAs) - Definition of Serotonin-dopamine antagonists (SDAs)","isPartOf":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website"},"datePublished":"2020-07-17T06:23:54+00:00","dateModified":"2020-07-17T06:23:54+00:00","author":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5"},"description":"A class of medications known as the atypical antipsychotics. both conventional antipsychotics and atypical antipsychotics are antagonists of dopamine receptors; however, the newer agents are also potent antagonists of serotonin receptors (5-HT2A). As a result of this distinctive receptor profile, SDAs may be more effective than conventional antipsychotics in reducing negative symptoms of schizophrenia. they also may produce fewer extrapyramidal symptoms (EPS) and decrease the risk for developing tardive dyskinesia with long-term use; however, SDAs and conventional antipsychotics are equally effective in treating the positive symptoms of schizophrenia.","breadcrumb":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/serotonin-dopamine-antagonists-sdas\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.healthbenefitstimes.com\/glossary\/serotonin-dopamine-antagonists-sdas\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/serotonin-dopamine-antagonists-sdas\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.healthbenefitstimes.com\/glossary\/"},{"@type":"ListItem","position":2,"name":"Serotonin-dopamine antagonists (SDAs)"}]},{"@type":"WebSite","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/","name":"Glossary","description":"Difinitions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5","name":"Glossary","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/"}]}},"_links":{"self":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/29375","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/comments?post=29375"}],"version-history":[{"count":1,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/29375\/revisions"}],"predecessor-version":[{"id":29376,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/29375\/revisions\/29376"}],"wp:attachment":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/media?parent=29375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/categories?post=29375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/tags?post=29375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}